1. Home
  2. LGVN vs GTBP Comparison

LGVN vs GTBP Comparison

Compare LGVN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.99

Market Cap

11.9M

Sector

Health Care

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.41

Market Cap

12.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGVN
GTBP
Founded
2014
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9M
12.1M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
LGVN
GTBP
Price
$0.99
$0.41
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
7.1M
798.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
$709,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.39
52 Week High
$1.92
$3.73

Technical Indicators

Market Signals
Indicator
LGVN
GTBP
Relative Strength Index (RSI) 72.52 33.71
Support Level $0.55 $0.41
Resistance Level $0.99 $0.59
Average True Range (ATR) 0.11 0.04
MACD 0.04 0.00
Stochastic Oscillator 80.42 22.64

Price Performance

Historical Comparison
LGVN
GTBP

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: